- Dual inhibition - a new perspective2005 | First Faculty of Medicine
- Dual inhibition - a new perspective of the treatment of hypercholesterolaemia2003 | First Faculty of Medicine
- Dual inhibition - new trend in the treatment of dyslipidemias2003 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Dual inhibition of topoisomerases enhances apoptosis in melanoma cells2010 | Faculty of Medicine in Hradec Králové
- Dual inhibition: the results of IMPROVE-IT study - what is important for patients with diabetes2015 | First Faculty of Medicine
- Twou sources of cholesterol and dual inhibition - a new perspective in hyperlipidemia treatment2004 | First Faculty of Medicine
- New concept in the treatment of cardiovascular diseases - dual inhibition of neutral endopeptidase and RAA system2017 | First Faculty of Medicine
- Involvement of mTOR Pathways in Recovery from Spinal Cord Injury by Modulation of Autophagy and Immune Response2021 | Second Faculty of Medicine
- Monitoring the dynamics of clinical and laboratory markers of chronic heart failure during 12 months of sacubitril/valsartan treatment2021 | First Faculty of Medicine
- ASCO 2020 virtual conference and treatment of lung cancer2020 | Publication without faculty affiliation
- Zoletorv - Pharmacological profile2017 | Faculty of Medicine in Pilsen
- Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from Benzohydrazides: Synthesis, Evaluation and Docking Study2023 | Faculty of Pharmacy in Hradec Králové
- Hydrazones of 4-(Trifluoromethyl)benzohydrazide as New Inhibitors of Acetyl- and Butyrylcholinesterase2021 | Faculty of Pharmacy in Hradec Králové
- 5-Aryl-1,3,4-oxadiazol-2-amines Decorated with Long Alkyl and Their Analogues: Synthesis, Acetyl- and Butyrylcholinesterase Inhibition and Docking Study2022 | Faculty of Pharmacy in Hradec Králové
- Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors2020 | Faculty of Pharmacy in Hradec Králové
- Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management2019 | First Faculty of Medicine
- Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events A Secondary Analysis of the COMPASS Trial2022 | Central Library of Charles University